Vijaya Diagnostic Centre Ltd

Vijaya Diagnostic Centre Ltd has announced the details for its 24th Annual General Meeting (AGM), scheduled for Thursday, September 24, 2026, at 11:00 AM IST. The meeting will be conducted via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The company has set Wednesday, September 16, 2026, as the cut-off date for determining voting rights for both remote e-voting and voting at the AGM. Remote e-voting will commence on Monday, September 21, 2026, at 9:00 a.m. and conclude on Wednesday, September 23, 2026, at 5:00 p.m. This date also serves as the record date for determining shareholder entitlement to any dividend declared for the financial year ended March 31, 2026.

Vijaya Diagnostic Centre Limited (VDCL) has submitted a report from its Audit Committee and Independent Directors, dated August 6, 2026. This report certifies the distribution of proceeds from fractional entitlements to eligible shareholders of Medinova Diagnostic Services Limited (MDSL) following their amalgamation. The scheme, sanctioned by the NCLT, involved a share exchange ratio of 1 VDCL share for every 22 MDSL shares. Fractional entitlements totaling 3,914 shares were consolidated and allotted to Catalyst Trusteeship Limited, who will distribute the proceeds to eligible shareholders after deducting expenses and taxes, as per SEBI Master Circular guidelines.

Vijaya Diagnostic Centre Ltd announced its unaudited financial results for the quarter ended June 30, 2026, reporting a significant 22.8% year-on-year revenue growth to ₹2,309.8 million. EBITDA increased by 34.0% to ₹985.4 million, and Profit After Tax (PAT) saw a 37.6% rise to ₹531.0 million. The company also experienced strong operational growth, with total tests increasing by 16.5% and total footfall by 12.7%. Key drivers included network expansion with new hub and spoke centers, and enhanced imaging technologies. The MD & CEO expressed satisfaction with the performance, highlighting revenue surpassing Q4 FY26 despite Q1 being a moderate season.

Vijaya Diagnostic Centre Ltd announced its unaudited financial results for the first quarter ended June 30, 2026, on both consolidated and standalone bases. The Board of Directors approved these results during a meeting held on August 06, 2026. The company also provided limited review reports on the financial results. The filing indicates that the company operates in a single segment: Diagnostic services.

Vijaya Diagnostic Centre's Q1 FY27 (quarter ended June 30, 2026) consolidated revenue came in at ₹230.98 Cr, up 22.8% YoY and 5.3% QoQ, essentially in line with Nuvama's pre-quarter estimate of 22% YoY growth. Consolidated PAT of ₹53.10 Cr grew 37.6% YoY (+10.8% QoQ), running ahead of Nuvama's 35.5% YoY PAT-growth estimate and its 26.4% EBITDA-growth call — actual EBITDA of ₹97.75 Cr grew 32.9% YoY. Basic EPS was ₹5.16 versus ₹3.76 a year ago. No exceptional or one-off items appear in either the standalone or consolidated statement this quarter, so the growth is on a clean, comparable base. The beat on profitability sat on margins: consolidated net profit margin expanded to 22.99% from 19.78% a year ago (+321 bps), and operating margin rose to 42.32% from 39.10% YoY, even as it eased from 43.54% in the seasonally stronger Q4 FY26 print. The margin print sits comfortably above management's own conservative FY27 guidance of an EBITDA margin above 40%, and the 22.8% YoY revenue growth is well inside the 'double-digit, volume-led' range management guided for on the Q4 FY26 call — so the quarter tracks ahead of, not just in line with, the outlook management gave in May 2026. Management has not issued a separate press release on this print (none available in the record), so there is no company framing to reconcile against the numbers beyond the standing FY27 guidance. On the corporate calendar, the quarter closed with HDFC Mutual Fund crossing a 5% stake (July 29, 2026) and a CFO transition — Narasimha Raju was appointed on July 9, 2026, meaning this print is effectively his first as finance chief, alongside a CTO resignation flagged in June. None of these are reflected in the reported numbers but bear watching for continuity in capital allocation and reporting cadence. Standalone PAT of ₹53.15 Cr (+36.1% YoY) tracks within a percentage point of the consolidated growth rate, so the two bases tell the same story this quarter.

HDFC Mutual Fund, through its various schemes, has acquired a 5.003% stake in Vijaya Diagnostic Centre Ltd. The disclosure was made under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The acquisition brings HDFC Mutual Fund's total holding to 51,47,641 equity shares, representing 5.003% of the company's paid-up equity share capital as of July 27, 2026. The total paid-up equity share capital of Vijaya Diagnostic Centre Ltd is Rs. 10,28,96,728/-.

Vijaya Diagnostic Centre Ltd has announced that its Board of Directors will convene on August 6, 2026. The primary agenda item is to consider and approve the standalone and consolidated un-audited financial results for the first quarter ended June 30, 2026. The company also noted that the trading window for its securities, closed since July 1, 2026, will remain shut until 48 hours after the announcement of these financial results, extending to August 8, 2026.

Vijaya Diagnostic Centre Ltd announced the appointment of Mr. Narasimha Raju K.A. as the new Chief Financial Officer (CFO) of the company, effective July 9, 2026. The decision was approved by the Board of Directors during a meeting held on July 9, 2026. Mr. Raju is a Chartered Accountant with over 20 years of experience in finance, accounting, corporate governance, and strategic leadership, including prior experience as CFO of the company from March 2021 to March 2025. His expertise spans IPOs, M&A, financial reporting, and regulatory compliance. He previously served as CFO of Yashoda Group of Hospitals.

Vijaya Diagnostic Centre Ltd has announced the appointment of Mr. Narasimha Raju K.A. as its new Chief Financial Officer (CFO), effective July 9, 2026. The decision was approved by the Board of Directors during a meeting held on the same day. Mr. Raju brings over 20 years of extensive experience in finance, accounting, corporate governance, and strategic leadership, with a background in Big Four audit and senior leadership roles across healthcare, diagnostics, renewable energy, and real estate sectors. Notably, he previously served as the CFO of Vijaya Diagnostic Centre from March 15, 2021, to March 26, 2025, and was instrumental in the company's IPO. His expertise is expected to further strengthen the company's financial management and strategic objectives.

abrdn Asia Ltd, on behalf of various funds it manages, has disclosed the sale of 133,199 shares in Vijaya Diagnostic Centre Limited. This transaction, executed via open market sale on June 29, 2026, resulted in a decrease of 0.1294% in their total shareholding. Following the sale, abrdn Asia Ltd's total holding in Vijaya Diagnostic Centre stands at 3,331,046 shares, representing 3.2373% of the total share capital.